This study was conducted to fulfill the Food and Drug Administration (FDA) post-marketing requirement and a Pediatric Investigation Plan requirement by the European Medicines Agency's (EMA) Pediatric Committee to assess GPB treatment in UCD patients <2 months of age. Here, GYPB is linked to urea cycle disorder.